## Helen A Shih

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7923554/publications.pdf

Version: 2024-02-01

204 papers 10,095 citations

52 h-index 94 g-index

208 all docs

 $\begin{array}{c} 208 \\ \\ \text{docs citations} \end{array}$ 

208 times ranked 9769 citing authors

#	Article	IF	CITATIONS
1	Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases. Journal of Clinical Oncology, 2012, 30, 419-425.	1.6	1,205
2	Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients. International Journal of Radiation Oncology Biology Physics, 2010, 77, 655-661.	0.8	873
3	Estimating Survival in Patients With Lung Cancer and Brain Metastases. JAMA Oncology, 2017, 3, 827.	7.1	543
4	Patient Study of In Vivo Verification of Beam Delivery and Range, Using Positron Emission Tomography and Computed Tomography Imaging After Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 920-934.	0.8	346
5	Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 82, 2111-2117.	0.8	321
6	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. Journal of Clinical Oncology, 2020, 38, 3773-3784.	1.6	223
7	Radiation Therapy in the Management of Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1992-2003.	3.6	198
8	Approximating convex Pareto surfaces in multiobjective radiotherapy planning. Medical Physics, 2006, 33, 3399-3407.	3.0	181
9	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). International Journal of Radiation Oncology Biology Physics, 2017, 99, 812-816.	0.8	163
10	Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Practical Radiation Oncology, 2016, 6, 217-225.	2.1	162
11	Improved Planning Time and Plan Quality Through Multicriteria Optimization for Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, e83-e90.	0.8	152
12	Screening for Genomic Rearrangements in Families with Breast and Ovarian Cancer Identifies BRCA1 Mutations Previously Missed by Conformation-Sensitive Gel Electrophoresis or Sequencing. American Journal of Human Genetics, 2000, 67, 841-850.	6.2	149
13	Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer, 2014, 120, 126-133.	4.1	141
14	The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. Journal of Neuro-Oncology, 2013, 112, 467-472.	2.9	137
15	Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1262-1269.	0.8	113
16	Proton therapy for lowâ€grade gliomas: Results from a prospective trial. Cancer, 2015, 121, 1712-1719.	4.1	113
17	Volumetric tomography of fluorescent proteins through small animals in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18252-18257.	7.1	112
18	Systematic analysis of biological and physical limitations of proton beam range verification with offline PET/CT scans. Physics in Medicine and Biology, 2009, 54, 4477-4495.	3.0	112

#	Article	IF	Citations
19	A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro-Oncology, 2018, 20, 666-673.	1.2	108
20	An Approach for Practical Multiobjective IMRT Treatment Planning. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1600-1607.	0.8	106
21	Isocitrate dehydrogenaseâ€mutant glioma: Evolving clinical and therapeutic implications. Cancer, 2017, 123, 4535-4546.	4.1	103
22	Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 101, 624-629.	0.8	102
23	Long-term Results of Intraoperative Electron Beam Irradiation (IOERT) for Patients With Unresectable Pancreatic Cancer. Annals of Surgery, 2005, 241, 295-299.	4.2	99
24	Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 550-558.	1.1	95
25	Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro-Oncology, 2016, 18, 863-872.	1.2	91
26	Outcomes of Proton Therapy for Patients With Functional Pituitary Adenomas. International Journal of Radiation Oncology Biology Physics, 2014, 90, 532-539.	0.8	88
27	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors. Neurosurgery, 2019, 84, E152-E155.	1.1	87
28	Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. Journal of Neurosurgery, 2016, 124, 106-114.	1.6	86
29	Simulation of prompt gamma-ray emission during proton radiotherapy. Physics in Medicine and Biology, 2012, 57, 5459-5472.	3.0	85
30	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 96, 406-413.	0.8	84
31	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nature Medicine, 2020, 26, 1280-1284.	30.7	83
32	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal of Radiation Oncology Biology Physics, 2020, 107, 334-343.	0.8	81
33	Planar fluorescence imaging using normalized data. Journal of Biomedical Optics, 2005, 10, 064007.	2.6	80
34	Visual Outcome and Tumor Control After Conformal Radiotherapy for Patients With Optic Nerve Sheath Meningioma. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1166-1172.	0.8	80
35	Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro-Oncology, 2021, 23, 284-294.	1.2	78
36	Germline Mutations in <i>BRCA1 </i> and <i> BRCA2 </i> in Breast-Ovarian Families From a Breast Cancer Risk Evaluation Clinic. Journal of Clinical Oncology, 2001, 19, 2247-2253.	1.6	76

#	Article	IF	Citations
37	Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database. Journal of Clinical Neuroscience, 2014, 21, 1490-1496.	1.5	76
38	Clinical Application of In-Room Positron Emission Tomography for In Vivo Treatment Monitoring in Proton Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 183-189.	0.8	74
39	Accuracy of Proton Beam Range Verification Using Post-Treatment Positron Emission Tomography/Computed Tomography as Function of Treatment Site. International Journal of Radiation Oncology Biology Physics, 2011, 79, 297-304.	0.8	72
40	Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro-Oncology, 2015, 17, 296-302.	1.2	72
41	Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey. International Journal of Radiation Oncology Biology Physics, 2016, 95, 336-343.	0.8	69
42	BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic. Journal of Clinical Oncology, 2002, 20, 994-999.	1.6	67
43	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Journal of Clinical Oncology, 2022, 40, 403-426.	1.6	67
44	Stereotactic radiation treatment for benign meningiomas. Neurosurgical Focus, 2007, 23, E5.	2.3	66
45	Proton Stereotactic Radiosurgery for the Treatment of Benign Meningiomas. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1428-1435.	0.8	66
46	Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. Journal of Neuro-Oncology, 2016, 126, 157-164.	2.9	64
47	A Comparison of Critical Structure Dose and Toxicity Risks in Patients with Low Grade Gliomas Treated with IMRT versus Proton Radiation Therapy. Technology in Cancer Research and Treatment, 2013, 12, 1-9.	1.9	61
48	PET imaging for treatment verification of ion therapy: Implementation and experience at GSI Darmstadt and MGH Boston. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2008, 591, 282-286.	1.6	60
49	Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. Journal of Thoracic Oncology, 2016, 11, 256-260.	1.1	59
50	Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. Neuro-Oncology, 2020, 22, 912-917.	1.2	59
51	Internal target volume determined with expansion margins beyond composite gross tumor volume in three-dimensional conformal radiotherapy for lung cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 613-622.	0.8	58
52	The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1069-1077.	0.8	58
53	Outcomes After Whole Brain Reirradiation in Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 82, e167-e172.	0.8	57
54	Radiotherapy planning for glioblastoma based on a tumor growth model: improving target volume delineation. Physics in Medicine and Biology, 2014, 59, 747-770.	3.0	55

#	Article	IF	CITATIONS
55	Projected Second Tumor Risk and Dose to Neurocognitive Structures After Proton Versus Photon Radiotherapy for Benign Meningioma. International Journal of Radiation Oncology Biology Physics, 2012, 83, e495-e500.	0.8	51
56	Evolution of cerebral microbleeds after cranial irradiation in medulloblastoma patients. Neurology, 2017, 88, 789-796.	1.1	49
57	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology, 2020, 22, 1359-1367.	1.2	49
58	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro-Oncology, 2018, 20, 1652-1660.	1.2	47
59	Proton Radiation Therapy for the Treatment ofÂRetinoblastoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, 863-869.	0.8	46
60	Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiotherapy and Oncology, 2019, 137, 95-101.	0.6	46
61	Brain Necrosis in Adult Patients After Proton Therapy: Is There Evidence for Dependency on Linear Energy Transfer?. International Journal of Radiation Oncology Biology Physics, 2021, 109, 109-119.	0.8	43
62	Single-Fraction Proton Beam Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations. International Journal of Radiation Oncology Biology Physics, 2014, 89, 338-346.	0.8	40
63	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro-Oncology, 2017, 19, now236.	1.2	39
64	Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. Journal of Neuro-Oncology, 2019, 142, 69-77.	2.9	39
65	The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. Journal of Neuro-Oncology, 2018, 138, 299-306.	2.9	37
66	Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. Journal of Neurosurgery, 2018, 128, 1123-1132.	1.6	37
67	Long-term impact of a faculty mentoring program in academic medicine. PLoS ONE, 2018, 13, e0207634.	2.5	37
68	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. Oncologist, 2019, 24, 671-679.	3.7	36
69	Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncology, The, 2022, 23, e62-e74.	10.7	36
70	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nature Communications, 2021, 12, 5954.	12.8	35
71	Prospective, Randomized Study of Radiation Dose Escalation With Combined Proton-Photon Therapy for Benign Meningiomas. International Journal of Radiation Oncology Biology Physics, 2017, 99, 787-796.	0.8	34
72	Proton Stereotactic Radiosurgery for Brain Metastases: A Single-Institution Analysis of 370 Patients. International Journal of Radiation Oncology Biology Physics, 2018, 101, 820-829.	0.8	34

#	Article	IF	Citations
73	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. International Journal of Radiation Oncology Biology Physics, 2022, 114, 60-74.	0.8	33
74	In Vivo Investigation of Breast Cancer Progression by Use of an Internal Control. Neoplasia, 2009, 11, 220-227.	<b>5.</b> 3	31
75	Planned Two-Fraction Proton Beam Stereotactic Radiosurgery for High-Risk Inoperable Cerebral Arteriovenous Malformations. International Journal of Radiation Oncology Biology Physics, 2012, 83, 533-541.	0.8	31
76	Automated delineation of the clinical target volume using anatomically constrained 3D expansion of the gross tumor volume. Radiotherapy and Oncology, 2020, 146, 37-43.	0.6	31
77	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nature Communications, 2022, 13, 1325.	12.8	31
78	Underutilization of radiation therapy in patients with glioblastoma. Cancer, 2014, 120, 238-243.	4.1	30
79	Radiotherapy planning for glioblastoma based on a tumor growth model: implications for spatial dose redistribution. Physics in Medicine and Biology, 2014, 59, 771-789.	3.0	30
80	Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant <i>IDH</i> glioma patients. Neuro-Oncology, 2016, 18, now100.	1.2	30
81	Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model. Radiotherapy and Oncology, 2020, 142, 154-161.	0.6	30
82	Radiation and chemotherapy for highâ€risk lower grade gliomas: Choosing between temozolomide and PCV. Cancer Medicine, 2020, 9, 3-11.	2.8	28
83	Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas. International Journal of Radiation Oncology Biology Physics, 2021, 109, 252-266.	0.8	28
84	Normalized Transillumination of Fluorescent Proteins in Small Animals. Molecular Imaging, 2006, 5, 7290.2006.00018.	1.4	27
85	Adult Atypical Teratoid/Rhabdoid Tumors. World Neurosurgery, 2016, 85, 197-204.	1.3	27
86	Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. Radiotherapy and Oncology, 2019, 130, 164-171.	0.6	27
87	Current status and recent advances in resection cavity irradiation of brain metastases. Radiation Oncology, 2021, 16, 73.	2.7	27
88	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clinical and Translational Radiation Oncology, 2019, 18, 39-45.	1.7	26
89	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nature Cancer, 2021, 2, 498-502.	13.2	26
90	The role of radiotherapy in the management of high-grade meningiomas. Chinese Clinical Oncology, 2017, 6, S5-S5.	1.2	25

#	Article	lF	Citations
91	Radiation therapy in acromegaly. Reviews in Endocrine and Metabolic Disorders, 2008, 9, 59-65.	5 <b>.</b> 7	24
92	Management of GBM: a problem of local recurrence. Journal of Neuro-Oncology, 2017, 134, 487-493.	2.9	24
93	Radiation tolerance of the optic pathway in patients treated with proton and photon radiotherapy. Radiotherapy and Oncology, 2019, 131, 112-119.	0.6	24
94	Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. Journal of Neuro-Oncology, 2013, 115, 411-419.	2.9	23
95	Mapping 15O Production Rate for Proton Therapy Verification. International Journal of Radiation Oncology Biology Physics, 2015, 92, 453-459.	0.8	23
96	Defining Treatmentâ€Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatmentâ€Induced Necrosis. Oncologist, 2020, 25, e1221-e1232.	3.7	23
97	Multicriteria plan optimization in the hands of physicians: a pilot study in prostate cancer and brain tumors. Radiation Oncology, 2017, 12, 168.	2.7	22
98	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 101, 845-853.	0.8	22
99	Outcomes and patterns of care in adult skull base chondrosarcomas from the SEER database. Journal of Clinical Neuroscience, 2014, 21, 1497-1502.	1.5	21
100	Unilateral Eye Findings: A Rare Herald of Acute Leukemia. Ocular Oncology and Pathology, 2016, 2, 166-170.	1.0	21
101	Genetic analyses for predictors of radiation response in glioblastoma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 704-710.	0.8	20
102	Pretreatment Growth Rate Predicts Radiation Response inÂVestibular Schwannomas. International Journal of Radiation Oncology Biology Physics, 2014, 89, 113-119.	0.8	20
103	The clinical target distribution: a probabilistic alternative to the clinical target volume. Physics in Medicine and Biology, 2018, 63, 155001.	3.0	20
104	Brachytherapy as an Adjuvant for Recurrent Atypical and Malignant Meningiomas. Neurosurgery, 2019, 85, E910-E916.	1.1	20
105	Turner syndrome and meningioma: Support for a possible increased risk of neoplasia in Turner syndrome. European Journal of Medical Genetics, 2014, 57, 269-274.	1.3	19
106	The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity. Advances in Radiation Oncology, 2017, 2, 391-397.	1.2	19
107	Deep Sequencing Identifies <i>IDH1</i> R132S Mutation in Adult Medulloblastoma. Journal of Clinical Oncology, 2015, 33, e27-e31.	1.6	18
108	The role of image-guided intensity modulated proton therapy in glioma. Neuro-Oncology, 2017, 19, ii30-ii37.	1.2	18

#	Article	IF	Citations
109	C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1024-1028.	0.8	18
110	Spatiotemporal Fractionation Schemes for Irradiating Large Cerebral Arteriovenous Malformations. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1067-1074.	0.8	17
111	Visual Outcomes after Proton Beam Irradiation for Choroidal Melanomas Involving the Fovea. Ophthalmology, 2016, 123, 369-377.	5.2	17
112	[18F]-Fluoromisonidazole Positron Emission Tomography/Computed Tomography Visualization of Tumor Hypoxia in Patients With Chordoma of the Mobile and Sacrococcygeal Spine. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1030-1036.	0.8	16
113	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist, 2019, 24, 193-201.	3.7	16
114	Late Effects of CNS Radiation Therapy. Cancer Treatment and Research, 2009, 150, 23-41.	0.5	15
115	Modeling Intracranial Second Tumor Risk and Estimates of Clinical Toxicity with Various Radiation Therapy Techniques for Patients with Pituitary Adenoma. Technology in Cancer Research and Treatment, 2011, 10, 243-251.	1.9	15
116	Outcomes of Proton Therapy for the Treatment of Uveal Metastases. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1044-1050.	0.8	14
117	Patterns of Failure Among Patients With Low-grade Glioma Treated With Proton Radiation Therapy. Practical Radiation Oncology, 2019, 9, e356-e361.	2.1	14
118	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. Translational Research, 2019, 208, 63-72.	5.0	13
119	Analysis of patient outcomes following proton radiation therapy for retinoblastoma. Advances in Radiation Oncology, 2017, 2, 44-52.	1.2	12
120	Estimating prognosis at the time of repeat whole brain radiation therapy for multiple brain metastases: The reirradiation score. Advances in Radiation Oncology, 2017, 2, 381-390.	1.2	12
121	Is Less, More? The Evolving Role of Radiation Therapy forÂBrain Metastases. International Journal of Radiation Oncology Biology Physics, 2015, 92, 963-966.	0.8	11
122	Practice Considerations for Proton Beam Radiation Therapy of Uveal Melanoma During the Coronavirus Disease Pandemic: Particle Therapy Co-Operative Group Ocular Experience. Advances in Radiation Oncology, 2020, 5, 682-686.	1.2	11
123	Post-operative radiation therapy to the surgical cavity with standard fractionation in patients with brain metastases. Scientific Reports, 2020, 10, 6331.	3.3	11
124	Fibromatosis: current strategies for treatment. Current Opinion in Orthopaedics, 2003, 14, 405-412.	0.3	10
125	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neuro-Oncology Practice, 2018, 5, 64-68.	1.6	10
126	Hypopituitarism After Cranial Irradiation for Meningiomas: A Single-Institution Experience. Practical Radiation Oncology, 2019, 9, e266-e273.	2.1	9

#	Article	IF	Citations
127	Proton therapy for head and neck paragangliomas: A single institutional experience. Head and Neck, 2020, 42, 670-677.	2.0	9
128	Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. Journal of Neuro-Oncology, 2015, 123, 75-84.	2.9	8
129	A Rare Finding of Schwannoma of the Vidian Canal: A Case Report. Journal of Neurological Surgery Reports, 2015, 76, e48-e51.	0.6	8
130	Outcome and Toxicity of Proton Therapy for Vestibular Schwannoma: A Cohort Study. Otology and Neurotology, 2021, 42, 1560-1571.	1.3	8
131	Oncology Scan—High-Grade Gliomas. International Journal of Radiation Oncology Biology Physics, 2013, 85, 283-285.	0.8	7
132	Feasibility of Using Distal Endpoints for In-Room PET Range Verification of Proton Therapy. IEEE Transactions on Nuclear Science, 2013, 60, 3290-3297.	2.0	7
133	Limbal Stem Cell Preservation During Proton Beam Irradiation for Diffuse Iris Melanoma. Cornea, 2017, 36, 119-122.	1.7	7
134	Clinical outcomes and toxicity of proton radiotherapy for vestibular schwannomas: a systematic review. Journal of Radiation Oncology, 2019, 8, 357-368.	0.7	7
135	Molecular analysis of episomal human papillomavirus type 16 DNA in a cervical carcinoma cell line. Virus Research, 1997, 51, 183-195.	2.2	6
136	Limitations of analytical dose calculations for small field proton radiosurgery. Physics in Medicine and Biology, 2017, 62, 246-257.	3.0	6
137	Modelling of late side-effects following cranial proton beam therapy. Radiotherapy and Oncology, 2021, 157, 15-23.	0.6	6
138	Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial. Neurosurgery, 2022, 90, 506-514.	1,1	6
139	Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. Journal of Neuro-Oncology, 2020, 148, 81-88.	2.9	5
140	Dosimetric Comparison of Proton Versus Photon Radiosurgery for Treatment of Pituitary Adenoma. Advances in Radiation Oncology, 2021, 6, 100806.	1.2	5
141	Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field). British Journal of Ophthalmology, 2022, 106, 518-521.	3.9	5
142	The Alliance AMBUSH Trial: Rationale and Design. Cancers, 2022, 14, 414.	3.7	5
143	Feasibility of using distal endpoints for In-room PET Range Verification of Proton Therapy. , 2012, 60, 3290-3297.		4
144	Brain Metastases From Melanoma: Therapy at the Crossroads. International Journal of Radiation Oncology Biology Physics, 2016, 96, 713-716.	0.8	4

#	Article	IF	CITATIONS
145	Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. World Neurosurgery, 2020, 133, e804-e812.	1.3	4
146	The path forward for radiation therapy in the management of low-grade gliomas. Neuro-Oncology, 2020, 22, 748-749.	1.2	4
147	The Interaction of Waiting Time and Patient Experience during Radiation Therapy: A Survey of Patients from a Tertiary Cancer Center. Journal of Medical Imaging and Radiation Sciences, 2020, 51, 40-46.	0.3	4
148	Proton Beam Therapy (For CNS Tumors)., 2018,, 709-722.		4
149	Advances in radiotherapy for brain metastases. Neuro-Oncology Advances, 2021, 3, v26-v34.	0.7	4
150	Does the greater power of pencil beam scanning reduce the need for a proton gantry? A study of headâ€andâ€neck and brain tumors. Medical Physics, 2021, , .	3.0	4
151	In Regard to Yamamoto et al. International Journal of Radiation Oncology Biology Physics, 2012, 84, 875-876.	0.8	3
152	Analysis of After-Hours Patient Telephone Calls in Two Academic Radiation Oncology Departments: An Opportunity for Improvement in Patient Safety and Quality of Care. Journal of Oncology Practice, 2016, 12, e487-e494.	2.5	3
153	Central Nervous System: Progress of Today and a Preview of Tomorrow. International Journal of Radiation Oncology Biology Physics, 2016, 94, 425-427.	0.8	3
154	Radiation Therapy for Malignant Gliomas: Current Options. , 2017, , 217-231.		3
155	Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. Nature Reviews Clinical Oncology, 2019, 16, 521-522.	27.6	3
156	Intracranial Activity of Gefitinib and Capmatinib inÂaÂPatient with Previously Treated Non–Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification. Journal of Thoracic Oncology, 2020, 15, e8-e10.	1.1	3
157	Use of Involuntary Emergency Treatment by Physicians and Law Enforcement for Persons With High-Risk Drug Use or Alcohol Dependence. JAMA Network Open, 2021, 4, e2120682.	5.9	3
158	Radiation Therapy for Pituitary Tumors. , 2017, , 559-579.		3
159	Radiation Therapy Pain Management: Prevalence of Symptoms and Effectiveness of Treatment Options. Clinical Journal of Oncology Nursing, 2019, 23, 514-521.	0.6	3
160	Advances in combined radiation therapy for the management of rectal cancer. Expert Review of Anticancer Therapy, 2003, 3, 471-483.	2.4	2
161	Reply to M.C. Chamberlain et al. Journal of Clinical Oncology, 2012, 30, 3316-3317.	1.6	2
162	Core Physics Competencies for Proton Therapy Training of Radiation Oncology and Medical Physics Residents and Fellows. International Journal of Radiation Oncology Biology Physics, 2014, 88, 971-972.	0.8	2

#	Article	IF	CITATIONS
163	Subject-specific brain tumor growth modelling via an efficient Bayesian inference framework. , 2018, 10574, .		2
164	Pseudoprogression in low-grade glioma. Translational Cancer Research, 2019, 8, S580-S584.	1.0	2
165	Fractionated radiotherapy versus stereotactic radiosurgery for pituitary adenomas. Nature Clinical Practice Neurology, 2008, 4, 134-135.	2.5	1
166	Radiosurgery as Salvage Therapy for Primary Central Nervous System Lymphoma. Radiosurgery, 2010, , 276-287.	0.1	1
167	ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA). Neuro-Oncology, 2015, 17, v3.4-v3.	1.2	1
168	Radiation Safety for Pregnant Workers at a Proton Facility. International Journal of Radiation Oncology Biology Physics, 2018, 100, 560-564.	0.8	1
169	NCOG-04. EFFECTS OF PROTON RADIATION ON BRAIN STRUCTURE AND FUNCTION IN LOW GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi173-vi173.	1.2	1
170	NCMP-22. TREATMENT-RELATED ADVERSE EFFECTS IN PATIENTS WITH MALIGNANT GLIOMA: ESTABLISHMENT OF KEY FEATURES FOR PSEUDOPROGRESSION AND TREATMENT-INDUCED NECROSIS Neuro-Oncology, 2018, 20, vi198-vi198.	1.2	1
171	The role of proton beam therapy in central neurocytoma: A single-institution experience. Practical Radiation Oncology, 2018, 8, e305-e311.	2.1	1
172	With Regard to the Brainstem, Size Matters Most. International Journal of Radiation Oncology Biology Physics, 2019, 103, 799-800.	0.8	1
173	Initial Approach to the Patient with Multiple Newly Diagnosed Brain Metastases. Neurosurgery Clinics of North America, 2020, 31, 505-513.	1.7	1
174	Repeat Radiation in the Brain: Managing Patients With Locally Recurrent Glioma. Seminars in Radiation Oncology, 2020, 30, 218-222.	2.2	1
175	ACR–ASTRO Practice Parameter for the Performance of Proton Beam Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 149-159.	1.3	1
176	An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma. Neuro-Oncology, 2021, 23, 1814-1815.	1.2	1
177	Pituitary Adenoma. , 2018, , 105-114.		1
178	Proton Radiation Therapy for Meningiomas. , 2010, , 651-656.		1
179	Multimodal Analysis of Vasogenic Edema in Glioblastoma Patients for Radiotherapy Planning. , 2014, , .		1
180	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 2022, 24, 358-383.	1.2	1

#	Article	IF	CITATIONS
181	A Comparison of Treatment Outcomes after Standard Dose (70 Gy) versus Reduced Dose (50 Gy) Proton Radiation in Patients with Uveal Melanoma. Ophthalmology Retina, 2022, 6, 1089-1097.	2.4	1
182	Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience. Neuro-Oncology, 2022, 24, 2180-2189.	1.2	1
183	In reply to Drs. Rubin and Hansen. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1593.	0.8	0
184	Reply to Drs. Mulvenna and Holt. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1194-1195.	0.8	0
185	Application of Current Radiation Delivery Systems and Radiobiology. , 2012, , 697-706.		0
186	NTCT-03CEREBRAL MICROBLEEDS AFTER WHOLE BRAIN RADIATION THERAPY IN MEDULLOBLASTOMA PATIENTS. Neuro-Oncology, 2015, 17, v172.3-v172.	1.2	0
187	BMET-06. IMPROVED SURVIVAL AND PROGNOSTIC ABILITY IN LUNG CANCER PATIENTS WITH BRAIN METASTASES: AN UPDATE OF THE GRADED PROGNOSTIC ASSESSMENT FOR LUNG CANCER USING MOLECULAR MARKERS (LUNG-molGPA). Neuro-Oncology, 2016, 18, vi27-vi27.	1.2	0
188	Eye Tumors. Medical Radiology, 2016, , 143-149.	0.1	0
189	In Reply to McClelland et al. International Journal of Radiation Oncology Biology Physics, 2018, 100, 804.	0.8	0
190	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. Neuro-Oncology, 2018, 20, vi56-vi57.	1.2	0
191	Immediate Radiation and Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2018, 101, 518.	0.8	0
192	Arteriovenous Malformation., 2018,, 63-73.		0
193	Radiation Therapy in Tumors of the Pituitary Gland. , 2018, , 1-20.		0
194	Brain Irradiation Paradigms for Childhood Central Nervous System Tumors. Contemporary Endocrinology, 2019, , 299-320.	0.1	0
195	Introduction to radiation therapy. , 2021, , 28-37.		0
196	Parkinsonism reversed from treatment of pineal non-germinomatous germ cell tumor., 2021, 12, 237.		0
197	In Reply to McClelland and Watson. International Journal of Radiation Oncology Biology Physics, 2021, 110, 622.	0.8	0
198	The Essential Anthony. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1123-1124.	0.8	0

#	Article	IF	CITATIONS
199	Brachytherapy for Recurrent High-grade Meningiomas: An Institutional Experience. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.8	O
200	Meningioma researchâ€"status quo and quo vadis. Chinese Clinical Oncology, 2017, 6, S1-S1.	1.2	0
201	Particle Therapy for the Treatment of Brain Metastases. , 2020, , 185-196.		O
202	Basic Radiobiology and Radiation Physics Primer. , 2020, , 271-279.		0
203	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. Neuro-Oncology, 2020, 22, ii147-ii147.	1.2	O
204	The Insanity of Addiction and My Devotion to the Addicted. Practical Radiation Oncology, 2022, , .	2.1	O